Streptozocin
As of the edition of 20 October 2026, Streptozocin is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Zanosar
- First approved
- 7 May 1982 (US)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Esteve Pharmaceuticals; 4 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Heart and blood vessels; Inherited and neonatal; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 4 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Earlier holder | 1982 to now |
| Teva | Acquired holder | 2013 to now |
| Nobelpharma | Applicant | 2014 to now |